Listed

Black Diamond Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2020

Filed with the SEC on Nov 10, 2020 and accepted by EDGAR at Nov 10, 2020, 07:17 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2020-07-01 to 2020-09-30$12.9mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2020-01-01 to 2020-09-30$30.5mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2020-07-01 to 2020-09-30−$18.5mus-gaap:OperatingIncomeLoss
Operating income9 months2020-01-01 to 2020-09-30−$46.4mus-gaap:OperatingIncomeLoss
Interest expense3 months2020-07-01 to 2020-09-30$0us-gaap:InterestExpense
Interest expense9 months2020-01-01 to 2020-09-30$1.0kus-gaap:InterestExpense
Net income3 months2020-07-01 to 2020-09-30−$17.9mus-gaap:NetIncomeLoss
Net income9 months2020-01-01 to 2020-09-30−$44.6mus-gaap:NetIncomeLoss
Operating cash flow9 months2020-01-01 to 2020-09-30−$36.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2020-01-01 to 2020-09-30$33.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2020-09-30$56.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-09-30$336.4mus-gaap:AssetsCurrent
Total assetsAt period end2020-09-30$346.4mus-gaap:Assets
Current liabilitiesAt period end2020-09-30$11.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-09-30$19.1mus-gaap:Liabilities
Shareholders' equityAt period end2020-09-30$327.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001701541-20-000032. Last ingested by Listed: Nov 10, 2026, 16:37 ET. Listed shows no prices and gives no investment advice.